Resources

Seegene announced that it has developed the world’s first variant diagnostic test, which that can simultaneously detect Covid-19 and screen for multiple virus variants. The Allplex SARS-CoV-2 Master Assay can detect ten different targets via primary real-time PCR...

Our vision: Being part of cancer diagnostics with our molecular biological tests and save lives. The procedure is indeed simple: The physician only needs e.g. a smear or a saliva  sample, send it to the lab, and after a short time, he knows if his patient is at risk...

When disposable medical equipment manufacturers design precision devices, friction between moving parts can be difficult to manage. Engineers typically use medical device lubricants, including oils, greases or dry surface coatings to smooth the delicate movements of...

Medical Technology is now available on all devices. Read it for free here. Robotic surgery has thrived since the first record use of a robot-assisted surgical in 1985. Over the past three decades, advancements in technology have opened the door for a new wave of...

Enzyre and Takeda Pharmaceutical have entered into a strategic collaboration to develop assays for the diagnosis and monitoring of congenital bleeding disorders. In December 2019, Enzyre entered a research collaboration with Takeda Pharmaceutical to develop a device...

Future of Clinical Trials: COVID-19 accelerates shift to direct-to-patient model ahyler Wed, 02/10/2021 - 16:51

Ensoma debuts with $70M, Takeda deal to pursue off-the-shelf genomic medicines aalidrus Wed, 02/10/2021 - 16:31

PacBio nets $900M from SoftBank to support its long-read sequencing goals chale Wed, 02/10/2021 - 10:29

Hospitals could cut emissions associated with some medical device use in half by opting instead for remanufactured single-use medical devices. The LCA evaluated the use of a remanufactured electrophysiology catheter compared with the use of original catheters for 16...

Like all of us, AAMI member companies were blindsided by COVID-19. But they pivoted quickly from their business plans, collaborated with competitors, and mobilized to ramp up production of critically needed medical devices and supplies—all while keeping employees...

WASHINGTON — The last time Senator Amy Klobuchar, the Minnesota Democrat, sat in the majority, her party was fawning over Silicon Valley. Lawmakers praised the ingenuity of Facebook and Amazon, while President Barack Obama and regulators fought alongside Google and...

The battle against single-use plastics has gained momentum in recent years, as people become more aware of the lasting environmental implications of using plastic items only once before throwing them away. There is growing pressure on companies to come up with...

The financial impact of COVID-19 on healthcare providers has been considerable. With experts predicting that half of all US hospitals would be operating in the red by the end of 2020, healthcare leaders have had to seek multiple ways to cut costs. The expansion… Visit...

“You did nothing wrong,” said the Department of Public Health contact tracer who called my spouse late on January 2nd, “you wore a mask and followed all the safety guidelines. We may never know ultimately how you got it.” The sentiment brought no relief – our whole...

2020 was an incredibly paradoxical year for those of us in biotech: the striking dichotomy of simultaneously experiencing agonizing tragedy alongside buoyant optimism. Read more. The post The Biotech Paradox of 2020: A Year In Review appeared first on Atlas Venture.

A look back at 2020 and to the future at Atlas Venture. View the newsletter. The post Atlas Venture’s 2020 Year in Review appeared first on Atlas Venture.

Novartis teamed up with Cadent Therapeutics on treatment-resistant depression back when the neuro-focused biotech was working under the radar. Five years later, the Swiss pharma is helping itself to the rest of Cadent’s pipeline in a deal worth $210 million upfront...

Five years after Novartis stepped up with a sizable deal that gave them worldwide rights to Surface Oncology’s lead cancer drug, GlaxoSmithKline is coming in at the other end of the pipeline, snagging a preclinical natural killer drug designed to whip up a more...

Over the course of my career in healthcare, I’ve been fortunate to serve in a leadership role through four IPOs and even more financing rounds. All told, I’ve raised well over $1.5 billion in capital. That means I’ve spent a lot of time thinking about dilution. By...

One of the biggest elephants in the room regarding starting and scaling young companies is the tension, often healthy but sometimes detrimental, that exist between CEOs and venture capital firms. By Philip Astley-Sparke, CEO of Replimune, as part of the From The...

Prioritization is a concept that we have become intimately aware of, given the continually blurred lines of personal and professional obligations in a 24/7 world. The good news is we all know we need to prioritize; the bad news is we need to find time and courage to...

After more than 20 years in the industry, Ivana Magovčević-Liebisch had done it all — except build a company from scratch. Then Bruce Booth at Atlas Venture mentioned a couple of TREM2 assets he was trying to snag from Amgen’s old neuroscience pipeline. Read more. The...

Local life sciences investor Atlas Venture is continuing its push into RNA therapies with a new company: Remix Therapeutics. Read more. The post RNA startup Remix raises $81M from Atlas, Arch Venture appeared first on Atlas Venture.